leflunomide has been researched along with Adenocarcinoma Of Kidney in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Huang, Q | 1 |
| Zhou, H | 1 |
| Wang, Y | 1 |
| Hu, X | 1 |
| Li, T | 1 |
1 other study available for leflunomide and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; beta Catenin; Carcinoma, Renal Cell; Cell Line | 2016 |